Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/3130
Título : Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)
Autor : Puente, Javier
González-del-Alba, Aranzazu
Sala-Gonzalez, Núria
Méndez-Vidal, María José
Pinto, Alvaro
Rodríguez, Ángel
Cuevas Sanz, José Miguel
Muñoz del Toro, Jacobo Rodrigo
Useros Rodríguez, Eduardo
García García-Porrero, Ángela
Vázquez, Sergio
Filiación: [Puente,J] Medical Oncology, Hospital Clínico San Carlos. Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC. Madrid, Spain. [González-del-Alba,A] Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain. [Sala-Gonzalez,N] Medical Oncology, ICO Girona, Hospital Josep Trueta, Girona, Spain. [Méndez-Vidal,MJ] Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC). Reina Sofía Hospital. University of Córdoba, Cordoba, Spain. [Pinto,A] Medical Oncology, University Hospital La Paz - IdiPAZ, Madrid, Spain. [Rodríguez,A] Medical Oncology, Hospital Universitario de León, León, Spain. [Cuevas Sanz,JM] Medical Oncology, Hospital Universitario de la Ribera, Alcira, Spain. [Muñoz del Toro,JR; Useros Rodríguez,E; García García-Porrero,A] Medical Department, Janssen-Cilag S.A., Madrid, Spain. [Vázquez,S] Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain.
Palabras clave : Metastatic castration-resistant prostate cancer
Abiraterone Acetate
Cabazitaxel
Chemotherapy
Sequence
Drug therapy
Prostatic neoplasms
Acetato de abiraterona
Quimioterapia
Neoplasias de la próstata
MeSH: Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma
Medical Subject Headings::Health Care::Environment and Public Health::Public Health::Epidemiologic Factors::Age Factors
Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged
Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Anemia
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Kaplan-Meier Estimate
Medical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Oxidoreductases::Alcohol Oxidoreductases::Lactate Dehydrogenases::L-Lactate Dehydrogenase
Medical Subject Headings::Diseases::Male Urogenital Diseases::Genital Diseases, Male::Genital Neoplasms, Male
Medical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance::Multivariate Analysis
Medical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Pain
Medical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Steroids::Pregnanes::Pregnadienes::Pregnadienediols::Prednisone
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models, Statistical::Proportional Hazards Models
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant
Medical Subject Headings::Geographical Locations::Geographic Locations::Europe::Spain
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons, Cyclic::Hydrocarbons, Alicyclic::Cycloparaffins::Cyclodecanes::Taxoids
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
Fecha de publicación : 5-Aug-2019
Editorial : BioMed Central
Cita Bibliográfica: Puente J, González-del-Alba A, Sala-Gonzalez N, Méndez-Vidal MJ, Pinto A, Rodríguez A, et al. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer. 2019;19(1):766.
Abstract: Background: To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the treatments most frequently administered. Methods: Observational, prospective study conducted in patients with histologically or cytologically confirmed prostate adenocarcinoma; documented metastatic castration-resistant disease; progression after first-line, docetaxel-based chemotherapy with or without other agents. Results: Of the 150 patients recruited into the study, 100 patients were prescribed abiraterone acetate plus prednisone (AAP), 44 patients received cabazitaxel plus prednisone (CP), and 6 patients received other treatments. Age (odds ratio [OR] 1.06, 95% [confidence interval] CI 1.01 to 1.11) and not elevated lactate dehydrogenase (LDH) levels (OR 0.33, 95% CI 0.14 to 0.76) were independently associated with the administration of AAP. Treatment with AAP was associated with significantly longer clinical/radiographic progression-free survival (hazard ratio [HR] 0.57, 95% CI 0.38 to 0.85) and overall survival (OS; HR 0.40, 95% CI 0.21 to 0.76) compared to CP, while no significant differences between the treatments were found regarding biochemical progression-free survival (PFS; HR 0.78 [95% CI 0.49 to 1.24]). However, in a post-hoc Cox regression analysis adjusted for potential confounders there were not differences between AAP and CP in any of the time-to-event outcomes, including overall survival. We observed no new safety signals related to either regimen. Conclusion: Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen. When controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials.
URI: http://hdl.handle.net/10668/3130
Versión del editor : https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5974-9
DOI: 10.1186/s12885-019-5974-9
ISSN : 1471-2407 (Online)
Appears in Collections:01- Artículos - IMIBIC. Instituto Maimónides de Investigación Biomédica de Córdoba

Files in This Item:
File Description SizeFormat 
Puente_EfficacyAndSafety.pdfArtículo publicado862,92 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons